Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OCTP.LSE
- Price
- -
- Stock movement down
- -0.01 (-4.17%)
- Company name
- Oxford Cannabinoid Technologies Holdings PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 125.17M
- Ent value
- 124.87M
- Price/Sales
- -
- Price/Book
- 64.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -89.78%
- 3 year return
- -70.32%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
OCTP.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 64.19 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.09B |
| EPS (TTM) | -0.01 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -6.63K |
| Operating income (TTM) | -11.92M |
| Net income (TTM) | -10.18M |
| EPS (TTM) | -0.01 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.13M |
| Net receivables | 1.66M |
| Total current assets | 2.79M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 2.79M |
| Accounts payable | 840.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 840.00K |
| Total liabilities | 840.00K |
| Shareholder's equity | 1.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.35K |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -5.12K |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -522.25% |
| Return on Assets | -365.02% |
| Return on Invested Capital | -522.25% |
| Cash Return on Invested Capital | -0.26% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| OCTP.LSE | S&P500 | |
| Current price drop from All-time high | -97.60% | - |
| Highest price drop | -97.60% | -56.47% |
| Date of highest drop | 5 Jun 2024 | 9 Mar 2009 |
| Avg drop from high | -72.27% | -11.07% |
| Avg time to new high | 766 days | 12 days |
| Max time to new high | 765 days | 1805 days |
COMPANY DETAILS
Marketcap
125.17M
Marketcap category
Small-cap
Description
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase " I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Employees
7
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found